Sanofi's formulation patents on multibillion-dollar Lantus are Invalidated by US PTE16 Dec 2018
Mylan achieves key milestone to provide US diabetes patients with more affordable generic version of Sanofi's Lantus insulin glargine vials.
Mylan has announced that the US Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in its inter partes review (IPR) proceedings and found all claims of Sanofi's Lantus (insulin glargine 100 Units/mL) formulation patents (US Patent Nos. 7,476,652 and 7,713,930) unpatentable.
Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes for the control of high blood sugar. Sanofi sells the product in vials (Lantus) and as a disposable injection pen (Lantus SoloSTAR). Mylan's 505(b)(2) New Drug Application (NDA) for generic versions of Lantus and Lantus SoloSTAR, co-developed with Biocon, is under active review by the FDA.
Mylan CEO Heather Bresch commented: "For years, Mylan has been investing in the development of a more affordable generic to insulin glargine for diabetes patients. The PTAB's favorable ruling that invalidates two Sanofi Lantus formulation patents is an important step forward in our journey to help address the needs of nearly 30 million Americans living with diabetes. We take seriously the responsibility to improve insulin access and are honored to be a part of the solution that will bring much-needed competition to this critical market."
In October 2017, Sanofi initiated patent infringement litigation against Mylan's NDA in the United States District Court for the District of New Jersey that includes these two formulation patents listed as covering Lantus as well as other patents listed as covering the Lantus SoloSTAR injection pen. That litigation is pending, and no trial date has been set.
Sanofi's total IQVIA sales for the 12 months ending Oct. 31, 2018, were approximately $2.14 billion for Lantus 100 Units/mL and about $4.39 billion for Lantus SoloSTAR.
New HCP Kit for automated impurity analysis of biotherapeutics
21 Jun 2019
Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows.Read more
Sanofi and Google to develop new healthcare Innovation Lab
20 Jun 2019
Collaboration aims to change how Sanofi develops new treatments and will focus on to better understand patients and diseases, to increase Sanofi’s operational efficiency, and to improve the experience of Sanofi’s patients and customers.Read more
Catalent to purchase BMS manufacturing facility
19 Jun 2019
Customers to have access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms.Read more
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products
18 Jun 2019
Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.Read more
Colorcon launches Opadry Enteric for use with hydro-alcoholic media
17 Jun 2019
A fully formulated one-step system providing simple preparation and ease-of-use for film coating.Read more
SenzaGen granted its first patent for GARD potency biomarker test
16 Jun 2019
Company can now offer an animal-free test method to quantify the strength of an allergenic effect.Read more
Affordable measles and rubella vaccines using NevoLine manufacturing platform
14 Jun 2019
Univercells' propriety bioproduction platform has already proven success.Read more
Leaf Expression Systems launches first line of Hypertrans research products
13 Jun 2019
Plant-expression deal for difficult to produce proteins, vaccines, metabolites and natural proteins.Read more
Clinical supply milestone reached for triple-negative breast cancer treatment
12 Jun 2019
PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.Read more
Combining IT and OT software to solve manufacturing’s most frequent challenges
11 Jun 2019
PTC and Rockwell Automation combine technologies to accelerate customers’ digital transformation initiatives.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation